Advertisement
UK markets open in 7 hours 46 minutes
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.44
    +0.08 (+0.10%)
     
  • GOLD FUTURES

    2,336.20
    -5.90 (-0.25%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,214.53
    -745.98 (-1.38%)
     
  • CMC Crypto 200

    1,428.07
    +13.31 (+0.94%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results

Here’s a look at some of the companies the Yahoo Finance team will be watching for you today.

Groupon (GRPN) is reportedly on the hunt for a buyer. Recode says some Groupon executives are trying to drum up interest in a sale. The stock has languished in recent months – despite better than expected earnings in the first quarter. Alibaba (BABA) has been mentioned as one potential suitor. It already owns about 6% of the company.

A big deal for Boeing (BA). New Zealand has agreed to buy four P8 Poseidon planes – at a cost of about $1.6B. The planes will replace part of New Zealand’s aging marine patrol fleet. The country’s defense minister says he hopes it will help catch illegal activity in the southern oceans.

KemPharm’s (KMPH) stock is in the spotlight on some good news. The company says the trial of its new ADHD drug met its goals opening the door to submitting a formal application with the FDA in 2019. KemPharm says it will continue collecting clinical data on the drug for the rest of this year.

Say goodbye to the user reviews on Netflix (NFLX). The streaming giant has been slowly eliminating the reviews – and will do away with them completely by the end of the summer. Users will still be able to give a show a thumbs up or thumbs down, though. Netflix says that helps it better tailor suggestions to your “unique tastes”.